BOSTON, Nov. 08, 2019 -- Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-addictive therapies for the treatment of chronic pain, today.

BOSTON, June 05, 2019 -- Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-addictive therapeutics for the treatment of chronic pain, today.

BOSTON, Sept. 04, 2019 -- Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-addictive therapies for the treatment of chronic pain, today.

GAITHERSBURG, Md., Dec. 16, 2019 -- NexImmune, a clinical-stage biopharmaceutical company developing novel immune-therapeutics based on a proprietary Artificial Immune.

BOSTON, June 11, 2019 -- Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-addictive therapeutics for the treatment of chronic pain, today.

- CNTX-4975 Phase 3 clinical development program fully enrolled - - VICTORY-1 pivotal and VICTORY-3 open-label topline results expected in Q1 2020; VICTORY-2 pivotal results.

BOSTON, Dec. 03, 2019 -- Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-addictive therapies for the treatment of chronic pain, today.

We recently asked Portfolio Manager Charlie Dreifus for an update and outlook for the Small-Cap Special Equity Strategy that he’s been managing at Royce since 1998 Continue reading...

-- Administration procedure designed to optimize physician and patient experience and convenience -- -- Company also shares interim analysis of 719 patients in VICTORY-3 Phase.